Contrasting Cholesterol Management Guidelines for Adults with CKD.
The Kidney Disease Improving Global Outcomes Lipid Work Group recommends statins for adults ≥50 years old with CKD. The American College of Cardiology/American Heart Association endorses statins for adults with atherosclerotic cardiovascular disease, adults with LDL cholesterol≥190 mg/dl, and adults 40-79 years old with LDL cholesterol=70-189 mg/dl and diabetes or a 10-year predicted risk for atherosclerotic cardiovascular disease ≥7.5% estimated using the Pooled Cohort risk equations. Using data from the Reasons for Geographic and Racial Differences in Stroke Study, we calculated the agreement for statin treatment between these two guidelines for adults 50-79 years old with CKD (eGFR<60 ml/min per 1.73 m(2) or albuminuria≥30 mg/g) not on dialysis. We assessed the validity of the Pooled Cohort risk equations in individuals with CKD. Study participants were enrolled between 2003 and 2007, and we report incident cardiovascular disease events (stroke and coronary heart disease) through December of 2010. Among 4726 participants with CKD, 2366 (50%) were taking statins, and 1984 (42%) were recommended statins by the American College of Cardiology/American Heart Association guideline but not taking them. Overall, 376 (8%) participants did not meet the American College of Cardiology/American Heart Association criteria for initiating statin treatment. Cardiovascular disease incidence was low (3.0/1000 person-years; 95% confidence interval, 0.1 to 5.9) among these participants. The Pooled Cohort risk equations were well calibrated (Hosmer-Lemeshow chi-squared=2.7, P=0.45) with moderately good discrimination (C index, 0.71; 95% confidence interval, 0.65 to 0.77). In conclusion, these guidelines show high concordance for statin treatment for adults with CKD.
Departments of Epidemiology.
Lisandro D
LD
Colantonio
Cardiovascular Institute, Mount Sinai School of Medicine, New York, New York;
Usman
U
Baber
Department of Hypertension, Medical University of Lodz, Lodz, Poland; and.
Maciej
M
Banach
Departments of Epidemiology.
Rikki M
RM
Tanner
Medicine, and.
David G
DG
Warnock
Departments of Epidemiology, Medicine, and.
Orlando M
OM
Gutiérrez
Medicine, and.
Monika M
MM
Safford
Department of Medicine, Division of Nephrology, University Hospital Würzburg, Würzburg, Germany.
Christoph
C
Wanner
Biostatistics, University of Alabama at Birmingham, Birmingham, Alabama;
George
G
Howard
Departments of Epidemiology, Medicine, and pmuntner@uab.edu.
Paul
P
Muntner
D000368:Aged; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D050197:Atherosclerosis / Q000517:prevention & control*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D017410:Practice Guidelines as Topic; D051436:Renal Insufficiency, Chronic / Q000150:complications*; D018570:Risk Assessment
D000924:Anticholesteremic Agents
cardiovascular disease; cholesterol; chronic kidney; disease; practice guidelines; statins